Product Description
Tropicamide is a safe drug used for pupillary dilation prior to a comprehensive eye exam or ocular procedure. Dilation is also necessary for specific intraocular procedures such as cataract surgery to reduce intraoperative complications and for better exposure of the cataract during surgery. Pupillary dilation is also necessary for retinal surgery and investigations of the posterior segment. The use of mydriatic agents such as tropicamide has, therefore, become ubiquitous in optical settings. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK541069/)
Mechanisms of Action: mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eyenovia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Greece, Italy
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Keratoconjunctivitis Sicca|Mydriasis|Retinitis Pigmentosa
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-511687-90-00 |
HORA-PDE6B-001 | P2 |
Recruiting |
Retinitis Pigmentosa |
2029-11-07 |
2025-05-02 |
Treatments |
|
2024-517456-35-00 |
UP-CLI-2023-01 | P2 |
Not yet recruiting |
Mydriasis |
2025-06-30 |
12% |
||
2023-507561-26-00 |
NGF0123 | P2 |
Completed |
Keratoconjunctivitis Sicca |
2024-11-22 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/17/2025 |
News Article |
OSRX Expands Ophthalmic Solutions with New Medications and Post-Op Kits to Patients' Doors |
|
10/23/2024 |
News Article |
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet® |
|
10/16/2024 |
News Article |
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo |
|
10/01/2024 |
News Article |
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device |